Skip to main content

Table 1 NHI price list of antihypertensive drugs

From: Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis

  Drug name Listed price as of April 2012 Listed date of FDC drugs
ARB+HCTZ FDC losartan (50 mg) + hydrochlorothiazide (6.25 mg) 146.4 December 2006
  valsartan (80 mg) + hydrochlorothiazide (6.25 mg) 120.9 March 2009
  candesartan (8 mg) + hydrochlorothiazide (6.25 mg) 143.6 March 2009
  telmisartan (40 mg) + hydrochlorothiazide (6.25 mg) 137.9 June 2009
ARB+CCB FDC valsartan (80 mg) + amlodipine (5 mg) 120.3 April 2010
  olmesartan (20 mg) + azelnidipine (16 mg) 158.1 April 2010
  candesartan (8 mg) + amlodipine (5 mg) 140.7 June 2010
  telmisartan (40 mg) + amlodipine (5 mg) 133.2 September 2010
ARB losartan (50 mg) 143.4  
  valsartan (80 mg) 114.8  
  candesartan (8 mg) 140.4  
  telmisartan (40 mg) 131.0  
  olmesartan (20 mg) 130.4  
HCTZ hydrochlorothiazide (25 mg) 5.6  
CCB amlodipine (5 mg) 23.1  
  azelnidipine (16 mg) 65.5  
  1. ARB: angiotensin-receptor blocker, CCB: calcium-channel blocker, FDC: fixed-dose combination, HCTZ: hydrochlorothiazide.
  2. This table created from the NHI Drug Price List as of April 2012. When various doses of combination drugs exist, a major combination that is used frequently was selected. A generic version of losartan was listed in June 2012 at a price of 86.0 yen for a 50 mg tablet, about 60% of the cost of the original drug.